LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lantern Pharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.64−0.03 (-4.05%)
Close on Oct 19, 2026
- Market cap
- $7.97M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.3287 (−83.85%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $7.97M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -196.80%
Fundamentals
- Net income
- -$18.65M
- EPS, diluted
- -$1.62
- Free cash flow
- -$15.68M
- Book value per share
- -$0.26
- Diluted shares
- 12M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$15.47M
Net income
-$18.65M
EPS, diluted
-$1.62
Free cash flow
–
Reported periodTrailing twelve months